Live
Migraine
Migraine is a neurological disorder that causes moderate-to-severe headaches. The pain often affects one side of the head, but can affect both. It is generally associated with nausea, light sensitivity and sound sensitivity. Other symptoms may include dizziness, vomiting, and difficulty thinking. In some cases, a migraine attack begins with a period of sensory disturbance known as an aura.
174trials recruiting now
United Statesmost trial sites (74)
400+mapped site locations
Pfizermost active sponsor
Trials by phase
Phase 1 tests safety, phase 2 tests whether it works, phase 3 compares it with standard care, phase 4 follows it after approval.
Countries with the most trials
Where trials are recruiting
Each dot is a site city; bigger dots have more recruiting trials. Showing up to 400 locations.
Lead sponsors
Pfizer · 9Beijing Tiantan Hospital · 7AbbVie · 6Mayo Clinic · 4University of Florence · 4University Hospital, Clermont-Ferrand · 4Children's Hospital Medical Center, Cincinnati · 3Danish Headache Center · 3
Newest recruiting trials
- Not applicable (device/behavioral)
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
- Not applicable (device/behavioral)
Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain
- Phase 3
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
- Phase 3
Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy
- Phase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 2, Phase 3
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
- Not applicable (device/behavioral)
Marine Lipids Ease Painful TMD
- Phase 1
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- Not applicable (device/behavioral)
Suppressive Functions of Regulatory T Cells in Migraine
- Phase 2
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
- Observational study
EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
- Not applicable (device/behavioral)
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
- Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
- Not applicable (device/behavioral)
The Effects of Physiotherapy in Migraine
- Early phase 1
Virtual Reality and Biofeedback for Adolescents With Chronic Dizziness
- Phase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 2
Study of EVO756 in Adults With Migraine
- Phase 4
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
- Observational study
The Neuroanatomical and Psychological Correlates of Suggestibility in Patients With Non-Responsive Chronic Migraine
- Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Not applicable (device/behavioral)
The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia
- Not applicable (device/behavioral)
High- vs Standard-Dose Intravenous Magnesium for Acute Headache
- Phase 4
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
- Phase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
- Not applicable (device/behavioral)
Sleep, Stress and Migraine - an Observational and Training Study
See all 174 on ClinicalTrials.gov →
General information only, not medical advice. Trial listings are written by sponsors; eligibility and contacts are on each official listing.